You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAminosalicylic Acid
Accession NumberDB00233  (APRD00749, EXPT00693)
TypeSmall Molecule
GroupsApproved
DescriptionAn antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid. [PubChem]
Structure
Thumb
Synonyms
4-amino-2-hydroxybenzoic acid
4-aminosalicylate
4-aminosalicylic acid
p-aminosalicylic acid
para-amino salicylic acid
para-aminosalicylic acid
PAS
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GranupasGranule, delayed release4 gOralLucane Pharma2014-04-07Not applicableEu
Nemasol Sodium Tab 500mgTablet500 mgOralIcn Canada Ltd.1966-12-312005-04-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PaserGranule, delayed release4 g/1OralJacobus Pharmaceutical Company, Inc.1995-02-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PamisylParke-Davis
RexipasBristol-Myers Squibb
RezipasBristol-Myers Squibb
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Aminosalicylate calcium
133-15-3
Thumb
  • InChI Key: XDWVNCOPMIEDJK-UHFFFAOYSA-L
  • Monoisotopic Mass: 344.032127
  • Average Mass: 344.336
DBSALT001939
Aminosalicylate sodium
133-10-8
Thumb
  • InChI Key: FVVDKUPCWXUVNP-UHFFFAOYSA-M
  • Monoisotopic Mass: 175.024537738
  • Average Mass: 175.1172
DBSALT000354
Calcium aminosalicylate trihydrate
6059-16-1
Thumb
  • InChI Key: IPLQYSPEGHNJCQ-UHFFFAOYSA-L
  • Monoisotopic Mass: 398.0638211
  • Average Mass: 398.381
DBSALT001940
Sodium aminosalicylate dihydrate
6018-19-5
Thumb
  • InChI Key: GMUQJDAYXZXBOT-UHFFFAOYSA-M
  • Monoisotopic Mass: 211.04566671
  • Average Mass: 211.149
DBSALT001938
Categories
UNII5B2658E0N2
CAS number65-49-6
WeightAverage: 153.1354
Monoisotopic: 153.042593095
Chemical FormulaC7H7NO3
InChI KeyWUBBRNOQWQTFEX-UHFFFAOYSA-N
InChI
InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)
IUPAC Name
4-amino-2-hydroxybenzoic acid
SMILES
NC1=CC(O)=C(C=C1)C(O)=O
Pharmacology
IndicationFor the treatment of tuberculosis
Structured Indications
PharmacodynamicsAminosalicylic acid is an anti-mycobacterial agent used with other anti-tuberculosis drugs (most often isoniazid) for the treatment of all forms of active tuberculosis due to susceptible strains of tubercle bacilli. The two major considerations in the clinical pharmacology of aminosalicylic acid are the prompt production of a toxic inactive metabolite under acid conditions and the short serum half life of one hour for the free drug. Aminosalicylic acid is bacteriostatic against Mycobacterium tuberculosis (prevents the multiplying of bacteria without destroying them). It also inhibits the onset of bacterial resistance to streptomycin and isoniazid.
Mechanism of actionThere are two mechanisms responsible for aminosalicylic acid's bacteriostatic action against Mycobacterium tuberculosis. Firstly, aminosalicylic acid inhibits folic acid synthesis (without potentiation with antifolic compounds). The binding of para-aminobenzoic acid to pteridine synthetase acts as the first step in folic acid synthesis. Aminosalicylic acid binds pteridine synthetase with greater affinity than para-aminobenzoic acid, effectively inhibiting the synthesis of folic acid. As bacteria are unable to use external sources of folic acid, cell growth and multiplication slows. Secondly, aminosalicylic acid may inhibit the synthesis of the cell wall component, mycobactin, thus reducing iron uptake by M. tuberculosis.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinunknown
inhibitor
HumanP35354 details
Inhibitor of nuclear factor kappa-B kinase subunit alphaProteinunknown
inhibitor
HumanO15111 details
Arachidonate 5-lipoxygenaseProteinunknown
inhibitor
HumanP09917 details
Group IIE secretory phospholipase A2Proteinunknown
unknown
HumanQ9NZK7 details
2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseProteinunknown
unknown
Mycobacterium tuberculosisP64143 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding50-60%
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityLD50=4 gm/kg (orally in mice); LD50=3650 mg/kg (orally in rabbits)
Affected organisms
  • Mycobacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Aminosalicylic Acid.Approved
AcarboseAminosalicylic Acid may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolAminosalicylic Acid may increase the anticoagulant activities of Acenocoumarol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Aminosalicylic Acid.Approved, Vet Approved
AlbiglutideAminosalicylic Acid may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Aldosterone.Experimental
AlogliptinAminosalicylic Acid may increase the hypoglycemic activities of Alogliptin.Approved
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Aminosalicylic Acid.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Alteplase.Approved
ALX-0081The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with ALX-0081.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Amcinonide.Approved
Ammonium chlorideThe serum concentration of Aminosalicylic Acid can be increased when it is combined with Ammonium chloride.Approved, Vet Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Aminosalicylic Acid.Approved
AncrodAminosalicylic Acid may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Anecortave.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Anistreplase.Approved
Antithrombin III humanAminosalicylic Acid may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanAminosalicylic Acid may increase the anticoagulant activities of Apixaban.Approved
ArdeparinAminosalicylic Acid may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Aminosalicylic Acid.Approved, Investigational
AstaxanthinThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Astaxanthin.Investigational
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Aminosalicylic Acid.Approved
BalsalazideAminosalicylic Acid may increase the anticoagulant activities of Balsalazide.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Batroxobin.Experimental
BcgThe therapeutic efficacy of Bcg can be decreased when used in combination with Aminosalicylic Acid.Investigational
BecaplerminAminosalicylic Acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Beclomethasone dipropionate.Approved, Investigational
BemiparinThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Bemiparin.Approved
BenazeprilAminosalicylic Acid may decrease the antihypertensive activities of Benazepril.Approved, Investigational
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Aminosalicylic Acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Betamethasone.Approved, Vet Approved
BivalirudinAminosalicylic Acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinzolamideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Brinzolamide.Approved
BromocriptineAminosalicylic Acid may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Budesonide.Approved
BumetanideAminosalicylic Acid may decrease the diuretic activities of Bumetanide.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Aminosalicylic Acid.Investigational
CanagliflozinAminosalicylic Acid may increase the hypoglycemic activities of Canagliflozin.Approved
CandoxatrilAminosalicylic Acid may decrease the antihypertensive activities of Candoxatril.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Aminosalicylic Acid.Approved
CaptoprilAminosalicylic Acid may decrease the antihypertensive activities of Captopril.Approved
CertoparinAminosalicylic Acid may increase the anticoagulant activities of Certoparin.Approved
ChlorpropamideAminosalicylic Acid may increase the hypoglycemic activities of Chlorpropamide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Ciclesonide.Approved, Investigational
CilazaprilAminosalicylic Acid may decrease the antihypertensive activities of Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Aminosalicylic Acid.Approved
Citric AcidAminosalicylic Acid may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Clocortolone.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Aminosalicylic Acid.Approved, Nutraceutical
Cortisone acetateThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Cortisone acetate.Approved
Dabigatran etexilateAminosalicylic Acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinAminosalicylic Acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidAminosalicylic Acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinAminosalicylic Acid may increase the hypoglycemic activities of Dapagliflozin.Approved
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Aminosalicylic Acid.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with dehydroepiandrosterone sulfate.Investigational
dersalazineAminosalicylic Acid may increase the anticoagulant activities of dersalazine.Investigational
DesirudinAminosalicylic Acid may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Desmoteplase.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Dexketoprofen.Approved
DextranAminosalicylic Acid may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Aminosalicylic Acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Aminosalicylic Acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Aminosalicylic Acid may increase the anticoagulant activities of Dextran 75.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Diclofenamide.Approved
DicoumarolAminosalicylic Acid may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Diflorasone.Approved
DiflunisalAminosalicylic Acid may increase the anticoagulant activities of Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Difluprednate.Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Aminosalicylic Acid.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Aminosalicylic Acid.Approved
DisopyramideAminosalicylic Acid may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Dorzolamide.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DulaglutideAminosalicylic Acid may increase the hypoglycemic activities of Dulaglutide.Approved
Edetic AcidAminosalicylic Acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanAminosalicylic Acid may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinAminosalicylic Acid may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilAminosalicylic Acid may decrease the antihypertensive activities of Enalapril.Approved, Vet Approved
EnalaprilatAminosalicylic Acid may decrease the antihypertensive activities of Enalaprilat.Approved
EnoxaparinAminosalicylic Acid may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Aminosalicylic Acid.Approved, Investigational
eplivanserineThe risk or severity of adverse effects can be increased when eplivanserine is combined with Aminosalicylic Acid.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Aminosalicylic Acid.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Aminosalicylic Acid.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Equilin.Approved
EstroneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Estrone sulfate.Approved
Etacrynic acidAminosalicylic Acid may decrease the diuretic activities of Etacrynic acid.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateAminosalicylic Acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatideAminosalicylic Acid may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FibrinolysinThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fibrinolysin.Approved
fluasteroneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fludrocortisone.Approved
FluindioneAminosalicylic Acid may increase the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Flurandrenolide.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluticasone Propionate.Approved
FondaparinuxAminosalicylic Acid may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumAminosalicylic Acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilAminosalicylic Acid may decrease the antihypertensive activities of Fosinopril.Approved
FurosemideAminosalicylic Acid may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateAminosalicylic Acid may increase the anticoagulant activities of Gabexate.Investigational
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Aminosalicylic Acid.Approved, Nutraceutical
GliclazideAminosalicylic Acid may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideAminosalicylic Acid may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideAminosalicylic Acid may increase the hypoglycemic activities of Glipizide.Approved
GlyburideAminosalicylic Acid may increase the hypoglycemic activities of Glyburide.Approved
HE3286The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with HE3286.Investigational
HeparinAminosalicylic Acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Higenamine.Investigational
HirulogAminosalicylic Acid may increase the anticoagulant activities of Hirulog.Experimental
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Aminosalicylic Acid.Approved, Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Hydrocortisone.Approved, Vet Approved
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Aminosalicylic Acid.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Aminosalicylic Acid.Approved, Nutraceutical
idraparinuxAminosalicylic Acid may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Aminosalicylic Acid.Approved, Withdrawn
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Aminosalicylic Acid.Approved, Investigational
ImidaprilAminosalicylic Acid may decrease the antihypertensive activities of Imidapril.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Indobufen.Investigational
Insulin AspartAminosalicylic Acid may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirAminosalicylic Acid may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineAminosalicylic Acid may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineAminosalicylic Acid may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanAminosalicylic Acid may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproAminosalicylic Acid may increase the hypoglycemic activities of Insulin Lispro.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Istaroxime.Investigational
Kct 0809The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Kct 0809.Investigational
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Aminosalicylic Acid.Investigational
LanreotideAminosalicylic Acid may increase the hypoglycemic activities of Lanreotide.Approved
LepirudinAminosalicylic Acid may increase the anticoagulant activities of Lepirudin.Approved
LiraglutideAminosalicylic Acid may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilAminosalicylic Acid may decrease the antihypertensive activities of Lisinopril.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with ME-609.Investigational
MecaserminAminosalicylic Acid may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Medrysone.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Melengestrol.Vet Approved
MesalazineAminosalicylic Acid may increase the anticoagulant activities of Mesalazine.Approved
MetforminAminosalicylic Acid may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Aminosalicylic Acid.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Methylprednisolone.Approved, Vet Approved
MifepristoneAminosalicylic Acid may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolAminosalicylic Acid may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Aminosalicylic Acid.Approved
MoexiprilAminosalicylic Acid may decrease the antihypertensive activities of Moexipril.Approved
MometasoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Mometasone.Approved, Vet Approved
NadroparinAminosalicylic Acid may increase the anticoagulant activities of Nadroparin.Approved
NafamostatAminosalicylic Acid may increase the anticoagulant activities of Nafamostat.Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Aminosalicylic Acid.Investigational
NateglinideAminosalicylic Acid may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Aminosalicylic Acid.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aminosalicylic Acid.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Aminosalicylic Acid.Investigational
OctreotideAminosalicylic Acid may increase the hypoglycemic activities of Octreotide.Approved, Investigational
Oleoyl estroneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Oleoyl estrone.Investigational
OlsalazineAminosalicylic Acid may increase the anticoagulant activities of Olsalazine.Approved
OmapatrilatAminosalicylic Acid may decrease the antihypertensive activities of Omapatrilat.Investigational
OtamixabanAminosalicylic Acid may increase the anticoagulant activities of Otamixaban.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Paramethasone.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Parnaparin.Approved
PasireotideAminosalicylic Acid may increase the hypoglycemic activities of Pasireotide.Approved
PentamidineAminosalicylic Acid may increase the hypoglycemic activities of Pentamidine.Approved
Pentosan PolysulfateAminosalicylic Acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Aminosalicylic Acid.Approved, Investigational
PerindoprilAminosalicylic Acid may decrease the antihypertensive activities of Perindopril.Approved
PhenindioneAminosalicylic Acid may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonAminosalicylic Acid may increase the anticoagulant activities of Phenprocoumon.Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aminosalicylic Acid.Approved
PioglitazoneAminosalicylic Acid may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PiretanideAminosalicylic Acid may decrease the diuretic activities of Piretanide.Experimental
PlasminThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Plasmin.Investigational
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Aminosalicylic Acid.Approved
PramlintideAminosalicylic Acid may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prasterone.Approved, Nutraceutical
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Aminosalicylic Acid.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Pregnenolone.Experimental
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Aminosalicylic Acid.Approved
Protein CAminosalicylic Acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanAminosalicylic Acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeAminosalicylic Acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
QuinaprilAminosalicylic Acid may decrease the antihypertensive activities of Quinapril.Approved, Investigational
QuinineAminosalicylic Acid may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Aminosalicylic Acid.Investigational
RamiprilAminosalicylic Acid may decrease the antihypertensive activities of Ramipril.Approved
RepaglinideAminosalicylic Acid may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineAminosalicylic Acid may decrease the antihypertensive activities of Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Aminosalicylic Acid.Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Reteplase.Approved
ReviparinAminosalicylic Acid may increase the anticoagulant activities of Reviparin.Approved
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Aminosalicylic Acid.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Rimexolone.Approved
RivaroxabanAminosalicylic Acid may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Rosiglitazone.Approved, Investigational
Salicylic acidAminosalicylic Acid may increase the anticoagulant activities of Salicylic acid.Approved, Vet Approved
SaxagliptinAminosalicylic Acid may increase the hypoglycemic activities of Saxagliptin.Approved
SCH-530348The risk or severity of adverse effects can be increased when SCH-530348 is combined with Aminosalicylic Acid.Investigational
SelexipagThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Aminosalicylic Acid.Approved, Vet Approved
SitagliptinAminosalicylic Acid may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SpiraprilAminosalicylic Acid may decrease the antihypertensive activities of Spirapril.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Aminosalicylic Acid.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Streptokinase.Approved
SulfadiazineAminosalicylic Acid may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleAminosalicylic Acid may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleAminosalicylic Acid may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulodexideAminosalicylic Acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SunitinibAminosalicylic Acid may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TemocaprilAminosalicylic Acid may decrease the antihypertensive activities of Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Tenecteplase.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Aminosalicylic Acid.Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Aminosalicylic Acid.Approved
TinzaparinThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Tinzaparin.Approved
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Aminosalicylic Acid.Approved
TixocortolThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Tixocortol.Approved
TolazamideAminosalicylic Acid may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideAminosalicylic Acid may increase the hypoglycemic activities of Tolbutamide.Approved
TorasemideAminosalicylic Acid may decrease the diuretic activities of Torasemide.Approved
TrandolaprilAminosalicylic Acid may decrease the antihypertensive activities of Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Aminosalicylic Acid.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Aminosalicylic Acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Aminosalicylic Acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Triamcinolone.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Aminosalicylic Acid.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Aminosalicylic Acid.Approved, Investigational
VerapamilVerapamil may increase the anticoagulant activities of Aminosalicylic Acid.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Aminosalicylic Acid.Approved
WarfarinAminosalicylic Acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranAminosalicylic Acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Aminosalicylic Acid may increase the anticoagulant activities of Ym150.Investigational
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Thomas M. Parkinson, Joseph P. Brown, Robert E. Wingard, Jr., “Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract.” U.S. Patent US4298595, issued January, 1975.

US4298595
General ReferencesNot Available
External Links
ATC CodesJ04AA02J04AA01J04AA03
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSDownload (73.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9356
Blood Brain Barrier-0.7101
Caco-2 permeable-0.852
P-glycoprotein substrateNon-substrate0.8405
P-glycoprotein inhibitor INon-inhibitor0.9777
P-glycoprotein inhibitor IINon-inhibitor0.9905
Renal organic cation transporterNon-inhibitor0.9337
CYP450 2C9 substrateNon-substrate0.8174
CYP450 2D6 substrateNon-substrate0.8358
CYP450 3A4 substrateNon-substrate0.7782
CYP450 1A2 substrateNon-inhibitor0.8645
CYP450 2C9 inhibitorNon-inhibitor0.8281
CYP450 2D6 inhibitorNon-inhibitor0.9627
CYP450 2C19 inhibitorInhibitor0.5778
CYP450 3A4 inhibitorNon-inhibitor0.7324
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9157
Ames testNon AMES toxic0.9388
CarcinogenicityNon-carcinogens0.8045
BiodegradationReady biodegradable0.6246
Rat acute toxicity1.5761 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9689
hERG inhibition (predictor II)Non-inhibitor0.9676
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Century pharmaceuticals inc
  • Hexcel chemical products
  • Panray corp sub ormont drug and chemical co inc
  • Lannett co inc
  • Consolidated midland corp
  • Jacobus pharmaceutical co
  • Bristol myers squibb co
Packagers
Dosage forms
FormRouteStrength
Granule, delayed releaseOral4 g
TabletOral500 mg
Granule, delayed releaseOral4 g/1
Prices
Unit descriptionCostUnit
Paser granules 4 gm packet3.59USD packet
Aminosalicylic acid powder2.4USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point150.5 dec °CPhysProp
water solubility1690 mg/L (at 23 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.89SANGSTER (1994)
pKa2.05 (at 25 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility11.8 mg/mLALOGPS
logP0.62ALOGPS
logP0.83ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)3.68ChemAxon
pKa (Strongest Basic)2.19ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area83.55 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity40 m3·mol-1ChemAxon
Polarizability14.29 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.18 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminosalicylic acids. These are salicylic acids carrying an amino group on the benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentAminosalicylic acids
Alternative Parents
Substituents
  • Aminosalicylic acid
  • Salicylic acid
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Benzoic acid
  • Substituted aniline
  • Benzoyl
  • Aminophenol
  • Phenol
  • Aniline
  • Primary aromatic amine
  • Vinylogous acid
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8. [PubMed:14742690 ]
  2. Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94. [PubMed:12463455 ]
  3. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19. [PubMed:16855178 ]
  4. Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6. [PubMed:12208114 ]
  5. Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7. [PubMed:9256165 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications...
Gene Name:
CHUK
Uniprot ID:
O15111
Molecular Weight:
84638.88 Da
References
  1. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000 Dec;95(12):3452-7. [PubMed:11151876 ]
  2. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
  3. Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18. [PubMed:11054378 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Iron ion binding
Specific Function:
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:
ALOX5
Uniprot ID:
P09917
Molecular Weight:
77982.595 Da
References
  1. Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82. [PubMed:2882965 ]
  2. Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51. [PubMed:6428914 ]
  3. Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2. [PubMed:6131674 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Phospholipase a2 activity
Specific Function:
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.
Gene Name:
PLA2G2E
Uniprot ID:
Q9NZK7
Molecular Weight:
15988.525 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
unknown
Actions
unknown
General Function:
Coenzyme transport and metabolism
Specific Function:
Not Available
Gene Name:
folK
Uniprot ID:
P64143
Molecular Weight:
20732.0 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. von Ritter C, Grisham MB, Granger DN: Sulfasalazine metabolites and dapsone attenuate formyl-methionyl-leucyl-phenylalanine-induced mucosal injury in rat ileum. Gastroenterology. 1989 Mar;96(3):811-6. [PubMed:2563347 ]
  2. Gorgulu S, Yagci G, Kaymakcioglu N, Ozkara M, Kurt B, Ozcan A, Kaya O, Sadir S, Tufan T: Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acid-induced colitis in rats. Dig Dis Sci. 2006 Mar;51(3):480-7. [PubMed:16614956 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 26, 2016 11:47